ImmunityBio, Inc. (NASDAQ:
IBRX) is one of the
Best Penny Stocks to Buy with the Highest Upside Potential. On September 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced new findings from its Phase 2 QUILT-3.055 study. The study tested ANKTIVA, which helps reverse lymphopenia.
The results show that reversing lymphopenia with ANKTIVA led to significantly longer median overall survival. Patients whose lymphocyte counts increased above 1,200 cells/μL had better survival outcomes. Moreover, ANKTIVA is the first therapy being tested to treat lymphopenia caused by cancer treatments like chemotherapy and radiotherapy.
Wall Street has been bullish on ImmunityBio, Inc. (NASDAQ:IBRX) since the release. On September 9, Justin Zelin from BTIG reiterated a Buy rating on the stock with a price target of $6. More recently, on September 17, H.C. Wainwright also reiterated a Buy rating on the stock with a price target of $8.
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company focused on developing therapies that strengthen the natural immune system to fight cancer and infectious diseases.
While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at
Insider Monkey.
